MAY 19, 2020 1:15 PM EDT | APAC MAY 20, 2020 4:15 PM CST

Immune Infiltration Influences the Survival of Pancreatic Cancer Patients

Speaker
  • Assistant Professor, Group Leader of the Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center
    BIOGRAPHY

Abstract

Rational: Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. Most PDAC patients die within the first two years, and only a small subgroup of patients exceeds this survival rate. So far, factors and pathways underlying long-term survivorship in PDAC are unknown. In a previous study we showed that high CD8/FoxP3 ratio is associated with a favorable outcome. Therefore, we aimed to reveal the immune-related key players that drive the long-term survivorship in PDAC patients.

Methods: The immune-related gene expression profiles of 10 PDAC patients survived and free of recurrence for ≥ 5 years, was compared to 10 PDAC patients in whom recurrence and death occurred within 6 months after surgery. Samples were profiled using the PanCancer Immune Profiling Panel of nanoString technology. Subsequently, a subgroup of samples was measured by the GeoMx Digital Spatial Profiler (DSP) to determine the spatial location of the immune cells.

Results: The immune microenvironment in long-term survivors was altered differentially than that of the short-term survivors. B cells were found to be highly expressed in long-term survivors by gene expression profile. The presence of B cells was confirmed by performing a high-plex proteomic analysis with spatial resolution (GeoMx DSP). B cells infiltrated to the tumor stroma together with T cells and antigen presenting cells in long-term survivors.

Conclusion: This is the first comprehensive study that compares the expression and the spatial infiltration of immune cells in PDAC patients with different survival rates. Our data demonstrate that long-term survivorship of PDAC patients is influenced by the presence of B cells in the tumor microenvironment. The role of B cells in PDAC disease is controversial. However, our findings illustrate that B cells interact with other compartments of the immune system and drive long-term survivorship in PDAC patients.

Hosein Aziz1, Lawlaw Saida1, Jasper Dumas2,4, Andrew Stubbs2,3, Yunlei Li2,3, Casper van Eijck1,4 and Dana A. Mustafa2,4

1 Department of Surgery, 2 Department of Pathology, 3 Division of Clinical Bioinformatics, 4 The Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center, Rotterdam, the Netherlands.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
Loading Comments...
Show Resources